There are currently 5-10 million people on a branded GLP-1 medication, but there is an estimated 50-60 million who are clinically eligible to receive Wegovy and have insurance coverage for it, and of those, millions could purchase it for a copay of less than $100/month
By focusing on the whole personrather than just the number on the scalewe help you stay in a position where you can continue doing the things you love, including helping others through plasma donation
Tesamorelin may be accessed via a named patient or specials route under specialist supervision, whilst retatrutide is currently restricted to clinical trial settings in the UK
Your Klinic provider will help you determine which form aligns with your lifestyle and health targets
The peptide promotes tissue granulation and organized epithelial cell proliferation, effectively rebuilding compromised gut walls
doi:10.1136/bmjopen-2015-010159 18